- Opinion
- [Reporter's view] A groundbreaking policy is needed
- by Lee, Tak-Sun Jul 24, 2023 05:26am
- Controversy is in full swing over Madopar, a Parkinson's disease drug that withdrew from the Korean market early this year due to profitability issues. Patients want Madopar again, saying that the only remaining generic drug after Madopar was withdrawn has severe side effects. Furthermore, it raises the question of calculating the drug price
- Opinion
- [Reporter's view]Time to think about price by indication
- by Eo, Yun-Ho Jul 19, 2023 05:20am
- Now is the time to think. The increasing number of non-insured indications and the steadily increasing number of indications for new drugs have now become quite a big snowball. In an age when a single drug has multiple indications and is used for multiple diseases, the emergence of drugs that target specific gene mutations and further activat
- Opinion
- [Reporter’s View]Kudos to Keytruda for filing 13 reimb apps
- by Eo, Yun-Ho Jul 5, 2023 05:45am
- A truly extraordinary case has emerged. MSD Korea has applied for the reimbursement of 13 Keytruda indications at once. This is an unprecedented event, the first time such a large amount of applications had been filed for a single drug since the positive list system was implemented for drug reimbursement in Korea. After submitting the ap
- Opinion
- [Reporter’s View] Gvn't policies hinder KOR pharma growth
- by Lee, Tak-Sun Jul 4, 2023 05:37am
- It seems that the pro-business policy the new administration has been implementing to promote Korea’s industries is not benefiting the domestic pharmaceutical companies at all. Rather, the companies have expressed their regrets on how the authorities have been implementing policies that hinder their corporate activities, such as those that
- Opinion
- [Reporter's view] Signs of concern about the Saxenda craze
- by Jun 29, 2023 05:56am
- Five years ago, there was a Saxenda craze in Korea. People rushed to the clinics because they could easily lose weight with self-injection once a day at home, and there were no central nervous system side effects, unlike existing obesity drugs, which are psychotropic drugs. The saying, 'There is no one in Gangnam who does not take Saxenda' w
- Opinion
- [Reporter's view] Where's the wrong answer note
- by Kim, Jin-Gu Jun 26, 2023 05:53am
- The government is preparing the '2nd National Health Insurance Comprehensive Plan' to be implemented for five years until 2028. The focus of the pharmaceutical industry is on drug spending policies. This is because it is expected to contain the framework of the entire reimbursement system, from new drugs to generics. In the first National
- Opinion
- [Reporter’s View] Closer look into Korea’s new drug access
- by Eo, Yun-Ho Jun 21, 2023 05:53am
- “Korea has low new drug access. It needs to be improved.” As much as the phrase comes to heart, we need to look more closely into the matter to correctly assess the situation. Recently, the Korean Research-based Pharmaceutical Industry Association (KRPIA) recently published a report on Korea’s current new drug release status based
- Opinion
- [Reporter's view] Homework left by ASCO 2023’ hot topic
- by Jung, Sae-Im Jun 16, 2023 05:53am
- There is one thing in common with the major studies that drew attention at this year's Annual Conference of the American Society of Clinical Oncology (ASCO 2023). It has achieved successful results in adjuvant therapy targeting early cancer where surgery is possible. New drugs used in terminal cancers, such as metastasis and recursation, have
- Opinion
- [Reporter's view] It's time to share the achievements
- by Lee, Seok-Jun Jun 13, 2023 05:43am
- Biopharmaceutical companies attend major overseas conferences in late May and early June. ASCO, EULAR, and BioUSA. During this period, it is said that key workers in the R&D and BD fields are not in Korea. Looking at BIO USA alone, more than 500 Korean companies participated in the event, second only to the US. It is truly a global conferenc
- Opinion
- [Reporter’s View]Rise of adjuvant therapies amid concerns
- by Eo, Yun-Ho Jun 5, 2023 05:37am
- Although it may not be the same, the concept of administering a drug for ‘prevention’ has been around for a while. Patients who have chronic diseases have been taking drugs to ‘manage’ their condition rather than treat it. Also, some drugs just exist to prevent a condition, like anticoagulants. The same has just recently been appli
